24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

BACKGROUND: The SAKK 19/05 trial investigated the safety and efficacy of the combined targeted therapy bevacizumab and erlotinib (BE) in unselected patients with advanced non-squamous non-small cell lung cancer (NSCLC). Although activating EGFR mutations were the strongest predictors of the response...

Descripción completa

Detalles Bibliográficos
Autores principales: Baty, Florent, Joerger, Markus, Früh, Martin, Klingbiel, Dirk, Zappa, Francesco, Brutsche, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372268/
https://www.ncbi.nlm.nih.gov/pubmed/28359318
http://dx.doi.org/10.1186/s12967-017-1174-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372268/
https://www.ncbi.nlm.nih.gov/pubmed/28359318
http://dx.doi.org/10.1186/s12967-017-1174-z

Ejemplares similares